Načítá se...
Current status of ABL tyrosine kinase inhibitors stop studies for chronic myeloid leukemia
ABL tyrosine kinase inhibitors (TKIs) dramatically improves chronic myeloid leukemia (CML) prognosis and most CML patients are now able to lead lives that are equivalent to those of healthy individuals. However, high cost to CML patients of long-term treatment and adverse effects (AEs) remain proble...
Uloženo v:
| Vydáno v: | Stem Cell Investig |
|---|---|
| Hlavní autor: | |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
AME Publishing Company
2016
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4981735/ https://ncbi.nlm.nih.gov/pubmed/27583255 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.21037/sci.2016.07.08 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|